Windtree Therapeutics, Inc.
WINT
$1.22
-$0.08-6.15%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -16.93% | -19.57% | -15.22% | -19.39% | -17.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.95% | 63.80% | 4.00% | -20.15% | -38.61% |
| Operating Income | -58.95% | -63.80% | -4.00% | 20.15% | 38.61% |
| Income Before Tax | 63.21% | 57.13% | 84.01% | 49.99% | 40.79% |
| Income Tax Expenses | 105.19% | 122.75% | 108.34% | -- | 17.40% |
| Earnings from Continuing Operations | 60.90% | 53.46% | 83.06% | 48.25% | 41.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.90% | 53.46% | 83.06% | 48.25% | 41.70% |
| EBIT | -58.95% | -63.80% | -4.00% | 20.15% | 38.61% |
| EBITDA | -58.69% | -63.85% | -4.08% | 20.04% | 38.55% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
